Management of hepatic metastases

被引:63
作者
Choti, MA
Bulkley, GB
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA
来源
LIVER TRANSPLANTATION AND SURGERY | 1999年 / 5卷 / 01期
关键词
D O I
10.1002/lt.500050113
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%, Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection, Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved, Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms. Copyright (C) 1999 by the American Association for the Study of Liver Diseases.
引用
收藏
页码:65 / 80
页数:16
相关论文
共 158 条
  • [1] Repeat hepatectomy for colorectal liver metastases
    Adam, R
    Bismuth, H
    Castaing, D
    Waechter, F
    Navarro, F
    Abascal, A
    Majno, P
    Engerran, L
    [J]. ANNALS OF SURGERY, 1997, 225 (01) : 51 - 60
  • [2] Place of cryosurgery in the treatment of malignant liver tumors
    Adam, R
    Akpinar, E
    Johann, M
    Kunstlinger, F
    Majno, P
    Bismuth, H
    [J]. ANNALS OF SURGERY, 1997, 225 (01) : 39 - 49
  • [3] ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647
  • [4] 5 YEARS CLINICAL EXPERIENCE WITH 5-FLUOROURACIL
    ANSFIELD, FJ
    CURRERI, AR
    SCHROEDER, JM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1962, 181 (04): : 295 - +
  • [5] UNDERSTANDING AND OPTIMIZING USE OF CONTRAST MATERIAL FOR CT OF THE LIVER
    BARON, RL
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1994, 163 (02) : 323 - 331
  • [6] CLINICAL-VALUE OF WHOLE-BODY POSITRON EMISSION TOMOGRAPHY WITH [F-18] FLUORODEOXYGLUCOSE IN RECURRENT COLORECTAL-CANCER
    BEETS, G
    PENNINCKX, F
    SCHIEPERS, C
    FILEZ, L
    MORTELMANS, L
    KERREMANS, R
    AERTS, R
    DEROO, M
    [J]. BRITISH JOURNAL OF SURGERY, 1994, 81 (11) : 1666 - 1670
  • [7] BENGMARK S, 1969, CANCER, V23, P198, DOI 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO
  • [8] 2-J
  • [9] NATURAL-HISTORY OF PATIENTS WITH UNTREATED LIVER METASTASES FROM COLORECTAL-CANCER
    BENGTSSON, G
    CARLSSON, G
    HAFSTROM, L
    JONSSON, P
    [J]. AMERICAN JOURNAL OF SURGERY, 1981, 141 (05) : 586 - 589
  • [10] Bismuth H, 1996, Surg Oncol Clin N Am, V5, P353